Form 4: BridgeBio Pharma Director Randal W. Scott Sells Shares Under 10b5-1 Plan

Director Randal W. Scott sold 2,500 shares of BridgeBio Pharma, Inc. common stock at $34 per share on March 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Randal W. Scott, a director of BridgeBio Pharma, Inc., reported a transaction involving the sale of company stock.
• On March 1, 2024, Scott sold 2,500 shares of common stock at a price of $34 per share.
• The sale was executed under a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.
• Following the transaction, Scott directly owns 5,000 shares and indirectly owns 6,500 shares through Thinking Bench Capital LLC.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock sale by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) trade in their company's stock. These filings provide transparency to the market regarding insider activity. The use of a 10b5-1 plan indicates that the insider's trading was pre-planned and not based on any material non-public information at the time of the trade.

Stakeholder Impact

• The stock sale by a director could be perceived neutrally by shareholders as it was conducted under a pre-arranged 10b5-1 trading plan.

Key Dates